Korean J Urol.  1992 Oct;33(5):806-811.

The role of serum prostate specific antigen in prostatic cancer and benign prostatic hyperplasia

• Kim CS
• Ahn TY

Abstract

Serum prostate specific antigen was measured in 26 patients with prostatic cancer, 83 patients with benign prostatic hyperplasia. 12 healthy men without prostate disease and 5 females as normal control using immunoradiometric assay. Reference intervals established for healthy men and women were 0.1-2.5 ng/ml and the proportion of PSA values exceeding the reference interval was 96.2% ror patients with prostate cancer and 62% for men with benign prostatic hyperplasia. Acid phosphatase (AP) was elevated above normal level (up to 4U/d1) in 9 of 26 (34.6%) prostatic cancer patients and in 2 of 83 (2.4%) benign prostatic hyperplasia patients. In prostatic carcinoma the sensitivity and specificity were 96.2% and 50.0% for PSA values of greater than 4 ng/ml and they were 88.5% and 86.0% for PSA concentrations of greater than 20 ng/ml, respectively. Serum PSA is considered to be a useful diagnostic tool for prostatic cancer if we determine the positive predictive value for serum PSA concentration above 20 ng /ml.

Keyword

prostate specific antigen; prostatic cancer; benign prostatic hyperplasia

MeSH Terms

Acid Phosphatase
Female
Humans
Immunoradiometric Assay
Male
Prostate*
Prostate-Specific Antigen*
Prostatic Hyperplasia*
Prostatic Neoplasms*
Sensitivity and Specificity
Acid Phosphatase
Prostate-Specific Antigen